TargTex
Curated by SignalProvides therapeutics for Glioblastoma multiformis
Overview
TargTex provides therapeutics for Glioblastoma Multiforme. The company uses the artificial intelligence algorithm to find out the correlation between a small molecule and a target that is overexpressed in Glioblastoma Multiforme. The company is in the clinical trial of phase 2 study for its allosteric antagonist of a calcium channel that impairs GBM progression. These calcium channels are small molecules having anti-cancer properties. The company has also developed a biocompatible hydrogel formulation that was successfully tested in mice where GBM cells were injected intracranially.
Key facts
- Founded
- 2019
- Headquarters
- Torres Vedras, Portugal
- Stage
- Sign up to view
- Industry
- Life Sciences Technology
Business model
- 3 products and services
- Sign up to view
Contact
- Primary office
- Sign up to view
- Sign up to view